Capricor Therapeutics, Inc. (CAPR)
8.95
+0.01
(+0.11%)
USD |
NASDAQ |
Oct 02, 16:00
9.02
+0.07
(+0.78%)
After-Hours: 20:00
Capricor Therapeutics EPS Diluted (Quarterly) : -0.7032 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.7032 |
| March 31, 2026 | -0.591 |
| December 31, 2025 | -0.6176 |
| September 30, 2025 | -0.5375 |
| June 30, 2025 | -0.5669 |
| March 31, 2025 | -0.5345 |
| December 31, 2024 | -0.1599 |
| September 30, 2024 | -0.3795 |
| June 30, 2024 | -0.3454 |
| March 31, 2024 | -0.3124 |
| December 31, 2023 | -0.0248 |
| September 30, 2023 | -0.2475 |
| June 30, 2023 | -0.2908 |
| March 31, 2023 | -0.3077 |
| December 31, 2022 | -0.3068 |
| September 30, 2022 | -0.2608 |
| June 30, 2022 | -0.2923 |
| March 31, 2022 | -0.322 |
| December 31, 2021 | -0.2563 |
| September 30, 2021 | -0.1702 |
| June 30, 2021 | -0.2077 |
| March 31, 2021 | -0.2318 |
| December 31, 2020 | -0.2051 |
| September 30, 2020 | -0.1975 |
| June 30, 2020 | -0.2303 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.3031 |
| December 31, 2019 | -0.3387 |
| September 30, 2019 | -0.4288 |
| June 30, 2019 | -0.5918 |
| March 31, 2019 | -0.7657 |
| December 31, 2018 | -1.050 |
| September 30, 2018 | -1.351 |
| June 30, 2018 | -1.420 |
| March 31, 2018 | -1.365 |
| December 31, 2017 | 4.175 |
| September 30, 2017 | -1.170 |
| June 30, 2017 | -1.569 |
| March 31, 2017 | -1.714 |
| December 31, 2016 | -2.10 |
| September 30, 2016 | -2.90 |
| June 30, 2016 | -2.60 |
| March 31, 2016 | -2.60 |
| December 31, 2015 | -2.10 |
| September 30, 2015 | -1.80 |
| June 30, 2015 | -1.90 |
| March 31, 2015 | -2.30 |
| December 31, 2014 | -1.647 |
| September 30, 2014 | -1.30 |
| June 30, 2014 | -1.30 |
| March 31, 2014 | -1.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | -0.6277 |
| SELLAS Life Sciences Group, Inc. | -0.0508 |
| Sionna Therapeutics, Inc. | -0.6619 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Cytokinetics, Inc. | -1.505 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -40.73M |
| Total Expenses (Quarterly) | 40.73M |
| Enterprise Value | 373.19M |
| Earnings Yield | -27.37% |
| Normalized Earnings Yield | -27.37 |